FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s ...
Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results